Navigation Links
Trubion Presents Preclinical Data on Its SCORPION(TM) Multispecific Therapeutics at the 2009 American Association of Cancer Research Annual Meeting
Date:4/22/2009

outcome thereof. These statements are based on current expectations and assumptions regarding future events and business performance and involve certain risks and uncertainties that could cause actual results to differ materially. These risks include, but are not limited to, risks associated with the development of SCORPION multispecific therapeutics, the clinical advancement of TRU-016, the company's Wyeth collaboration, including Wyeth's control over development timelines, the risks that the Company is unable to advance its clinical development programs and regulatory applications and action at the rate it expects, and such other risks as identified in the company's annual report on Form 10-K for the period ended December 31, 2008, and from time to time in other reports filed by Trubion with the U.S. Securities and Exchange Commission. These reports are available on the Investors page of the company's corporate Web site at http://www.trubion.com. Trubion undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.

    Contact:
    Jim DeNike
    Senior Director, Corporate Communications
    Trubion Pharmaceuticals, Inc.
    (206) 838-0500
    jdenike@trubion.com
   http://www.trubion.com

    Waggener Edstrom Worldwide Healthcare
    Amy Petty
    Senior Account Executive
    (617) 576-5788
    amyp@waggeneredstrom.com

TRBN-SCORP


'/>"/>
SOURCE Trubion Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Trubion Pharmaceuticals, Inc. Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Systemic Lupus Erythematosus (SLE)
2. Trubion Pharmaceuticals Inc. Announces Work-Force Reductions and Restructuring
3. Trubion Announces Presentations at Upcoming Investor Conferences
4. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results
5. Trubion Announces Presentations at Upcoming Investor Conferences
6. Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis
7. Trubion Pharmaceuticals Wins Patent Opposition - Genentech / Biogen Idec European Patent Revoked
8. Trubion Pharmaceuticals to Present at Fall 2008 Morgan Stanley Global Healthcare Unplugged Conference in New York
9. Trubion Pharmaceuticals to Present at the 7th Annual Needham & Company Biotechnology & Medical Technology Conference
10. Trubion Announces Presentations at April/May Investor Conferences
11. Trubion Pharmaceuticals Inc. Reports Fourth-Quarter and Year-Ended 2007 Financial Results and Provides 2008 Financial Outlook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... ... July 01, 2015 , ... Apex Therapeutics announced today that company ... Philadelphia, PA. , The presentation took place on Tuesday, June 16 and ... the development of APX3330 for the treatment of pancreatic cancer. A copy of ...
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... ... sterilized to combat pathogen transmission. CTI’ new Medical Joysticks have an impermeable ... devices now have an operator control device that will increase healthcare worker safety ...
(Date:7/1/2015)... YORK , July 1, 2015  UCB, ... G ), a global leader in designing, transforming, ... Aecus Innovation Award in recognition of their close ... efficiencies in UCB,s global business services (GBS) finance ... service providers and clients that work together effectively ...
(Date:6/30/2015)... 1, 2015 R-Japan Co.,Ltd. obtained the license of ... Regenerative Medicine from the Ministry of Health, Labour and Welfare ... The fact that R- Japan ... auditing from Pharmaceuticals and Medical Devices Agency (PMDA) on May ... to provide stem cell manufacturing service to medical institutions. As ...
Breaking Biology Technology:Apex Therapeutics Presented Company Overview at This Year’s BIO International Convention in Philadelphia, PA 2Sanitized Medical Joysticks for a Safer and Healthier Work Environment 2UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 2UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 3UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 4UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 5R-Japan Obtained Autologous Stem Cell Manufacturing License from the Ministry of Health, Labour and Welfare 2
... 22 Accelerated Community Oncology,Research Network (ACORN) ... and clinical trial network, announced today,that it ... of Business Development.,Webb brings a successful record ... has an exceptional background of work in ...
... Symbol: MS, - US$10 million received based on ... pivotal multiple sclerosis trial - EDMONTON, Sept. 22 ... in the treatment of multiple sclerosis (MS), today,announced that ... its,partner, Eli Lilly and Company., The milestone payment ...
... the Effects of Oral Calcitonin, a,combination of Salmon ... CEDAR KNOLLS, N.J., Sept. 22 Emisphere,Technologies, ... Novartis Pharma AG,and Nordic Bioscience have completed recruitment ... and efficacy of an oral formulation of,salmon calcitonin ...
Cached Biology Technology:ACORN Contract Research Organization Appoints Tara Webb as Senior Director of CRO Business Development 2ACORN Contract Research Organization Appoints Tara Webb as Senior Director of CRO Business Development 3BioMS Medical announces receipt of milestone payment from Eli Lilly and Company 2Emisphere Announces Recruitment Phase III Study for Oral Osteoarthritis Treatment 2Emisphere Announces Recruitment Phase III Study for Oral Osteoarthritis Treatment 3
(Date:6/30/2015)... -- To bolster its efforts and commitment to fighting cyber ... addition of two new team members. ... David Raviv will act as head of strategic alliances. ... providing the most secure solutions for the enterprise market. ... Technologies, a provider of security and management products, which was ...
(Date:6/30/2015)... Genisphere announced Tom Bliss ... further develop Genisphere,s therapeutics capabilities and portfolio. Mr. Bliss ... much of the last 25 years in leadership positions ... Johnson & Johnson. Tom started his career in Investment ... Finance. He graduated from Dartmouth College with a BA ...
(Date:6/29/2015)... Research and Markets( http://www.researchandmarkets.com/research/zj7h4f/latin_america ) has ... Sensors Market - Growth, Trends & Forecasts (2014-2020)" ... Biomedical Sensors market is estimated at $0.65 billion by ... 2014-2020 The near future will bring Biomedical ... each individual. These sensors can be set to trigger ...
Breaking Biology News(10 mins):HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3Latin America Biomedical Sensors Market Report 2015-2020 2
... deadly 1918 Spanish influenza pandemic is why it struck ... such as St. Louis spared the fate of the ... health measures? What made the difference, according to two ... (NIH), was not only how but also how rapidly ...
... cell came from remain distinct even after the cell becomes ... in the February 1 issue of Cancer Research. , ... quest to understand the causes of childhood brain cancers, according ... O. Schnuck Family Professor of Neurology at Washington University School ...
... that the risk of HIV transmission may be highest ... a study published in the April 1 issue of ... infection accounted for nearly half of all transmission occurrences ... Canada. , Bluma Brenner, PhD, and Mark Wainberg, PhD, ...
Cached Biology News:Rapid response was crucial to containing the 1918 flu pandemic 2Rapid response was crucial to containing the 1918 flu pandemic 3Rapid response was crucial to containing the 1918 flu pandemic 4Genetic fingerprints identify brain tumors' origins 2Risk of HIV transmission highest early in infection 2
Competitors to lower non-specific signal...
... anti-rabbit IgG FITC is used as ... staining on tissues or culture cells ... in rabbits. It is highly recommended ... omitting the primary antibody, be included ...
Complete cell culture media with cytokines...
8 different frozen tissues are mounted on positively charged glass slides...
Biology Products: